{"hq_id":"hq-c-org-000620","name":"Fumonisin B2 (FB2)","context":"human_adult","timestamp":"2026-08-28T01:29:10.974Z","risk_level":"moderate_to_high","risk_profile":{"magnitude":{"mean":0.407895,"weightedMean":0.407895,"std_dev":0.099688,"confidence_interval_95":[0.5,0.5],"source_positions":[{"source":"IARC","year":2002,"value":0.5,"weight":0.41},{"source":"HQ_DIRECT","year":2026,"value":0.3,"weight":0.35}]},"confidence":{"mean":0.672632,"weightedMean":0.672632,"std_dev":0.159501,"confidence_interval_95":[0.82,0.82],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.5,"weight":0.35},{"source":"IARC","year":2002,"value":0.82,"weight":0.41}]},"recency":{"mean":0.730263,"weightedMean":0.730263,"std_dev":0.24922,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":1,"weight":0.35},{"source":"IARC","year":2002,"value":0.5,"weight":0.41}]},"methodology":{"mean":0.861842,"weightedMean":0.861842,"std_dev":0.149532,"confidence_interval_95":[1,1],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.7,"weight":0.35},{"source":"IARC","year":2002,"value":1,"weight":0.41}]},"specificity":{"mean":0.828289,"weightedMean":0.828289,"std_dev":0.084735,"confidence_interval_95":[0.92,0.92],"source_positions":[{"source":"HQ_DIRECT","year":2026,"value":0.92,"weight":0.35},{"source":"IARC","year":2002,"value":0.75,"weight":0.41}]},"consensus":{"exists":false,"strength":0.335413,"disagreement_magnitude":0.319781,"warning":"limited_synthesis"}},"interpretation":{"summary":"Regulatory agencies show substantial disagreement. IARC classifies as higher risk (50th percentile), while HQ_DIRECT concludes lower risk (30th percentile).","confidence_note":"Moderate-quality evidence base.","context_note":null,"warning":"limited_synthesis"},"sources":[{"id":"fb2_116355-84-1_iarc_2b_fumonisin_10-dehydroxy_maize","type":"regulatory","title":"Fumonisin B2 FB2 CAS 116355-84-1 C34H59NO14 IARC Group 2B Monograph 82 2002; 10-Dehydroxy-FB1 Structural Analog Sphinganine Ceramide Synthase CERS Inhibition Same Mechanism FB1; FB1:FB2:FB3 Ratio 60-70:20-25:5-10% Co-Occurrence Maize Fusarium verticillioides proliferatum; EFSA 2005 TDI 1 µg/kg bw/day Sum FB1+FB2+FB3; EU 1881/2006 Unprocessed Maize 4000 µg/kg Sum Fumonisins; Sa/So Ratio Biomarker Total Fumonisin Exposure; Nixtamalization Alkaline Hydrolysis Tricarballylic Ester 50-90% HFB2 Reduction; LC-MS/MS ELISA OPA Fluorescence Derivatization HPLC Detection; ELEM PPE Veterinary Disease Combined FB1+FB2 Natural Exposure; Maillard N-Carboxymethyl-FB2 Heat Masking","year":2002}],"sources_scope":"record","warnings":["limited_synthesis"],"meta":{"synthesis_version":"1.1.0","config_version":"1.1.0","n_sources":2,"db_version":37},"schema":"synthesis","_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult","human_child","aquatic_life","human_teen","human_elderly","human_infant","human_pregnant"]}